+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

ICH Stability Requirements and Challenges - Webinar

  • ID: 4899610
  • Webinar
  • September 2018
  • Region: Global
  • 180 Minutes
  • Compliance Online
1 of 2
Why Should You Attend:

Performing stability studies is often considered a routine task in the development cycle. However, if they are not designed and executed properly the results can be disastrous. Ineffective stability programs can lead to an assignment of shortened shelf life and/or delays in regulatory approvals. Given the options outlined in the ICH stability guidance, it is important to understand which options apply and how to implement them for your product.

This presentation will cover the ICH stability requirements, how to design the programs taking into account the drug product specifics and common challenges which can occur during these programs.

Areas Covered in the Webinar:

Background and Overview of ICH Q1
What are the requirements for stability programs
What are the analytical method requirements, what needs to be measured
Stability indicating methods – what are they?
Designing Stability Studies
Standard programs vs matrixing vs. bracketing
ANDA stability requirements
Data Analysis
Tracking and trending
OOS vs OOT
Setting specifications and shelf life
Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Dr. Wayland Rushing is a technical expert in chemistry, manufacturing and controls (CMC) program design, analytical development and regulatory submissions. Over his 15-year career, he has led CMC development programs for a wide array of biopharmaceuticals, including parenterals, inhalation drugs, and other pharmaceuticals with complex delivery systems.

Dr. Rushing is a subject matter expert in HPLC and GC method development and validation, extractables and leachables program design and regulatory submission requirements; has drafted multiple IND and NDA submissions; and assists ABC clients in responding to FDA deficiency letters. He currently serves on Parenteral Drug Association (PDA) advisory committees for Technology Transfer and Elastomeric Closures and Seals Presentation Summary and was co-author of PDA TR 65, Technology Transfer.
Note: Product cover images may vary from those shown
Adroll
adroll